2Yip HK, Wu C J, Chang HW, et al. Levels and values of serum high - sensitivity C - reactive protein within 6 hours after the onset of acute myocardial infarction [ J ]. Chest, 2004,126(5 ) : 1417-1422.
3Hojo Y, Ikeda U, Ueno S, et al. Expression of matrix metalloproteinase in patients with aeute myoeardial infaretion[J]. JpnCircJ, 2001, 65(2) :71-75.
4Musial J, Undas A, Gajewski P, et al. Anti - inflammatory effects of simvastatin in subjects with hypercholesterolemia[ J ]. Int J Cardiol, 2001, 77 (223) :247-253.
2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.
5Wilson AM, Swan JD,Ding H, et al. Widespread vascularproduction of C-reactive protein (CRP)and a relationship betweenserum CRP,plaque CRP and intimal hypertrophy [J]. Atherosclerosis,2007,191(1):175-181.
6Blagojevic A, Delaney JA, Levesque LE, et al. Investigation of aninteraction between statins and clopidogrel after percutaneouscoronary intervention a cohort study [J]. Pharmacoepidemiol DrugSaf,2009,18(5):362-369.
7Nozue T,Yamamoto S,Tohyama S,et al.Treatment with statin onatheroma regression evaluated by intravascular ultrasound withVirtual.Histology (TRUTH Study):rationale and design [J]. Circ J,2009,73(2):352-355.
8Puddu P,Muscari A, Puddu GM, et al. The complexity of plateletmetabolism and its contribution to atherothrombosis[J].Acta Cardio,2009,64(2):157-165.
9Nozue T,Fukui K,Yamamoto S,et al.C-Reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: The extended TRUTH study[J].J Atheroscler Thromb,2013,20(9) : 717-725.
10Graner M, Tikkanen E, Rimpila O, et al.Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain[J].Ann Med,2013,45(4):322-327.
